LABORATOIRES PARIS ELYSEES
ActiveSummary
LABORATOIRES PARIS ELYSEES has been active since 2013 and the Belgian Official Gazette contains no insolvency or warning signals. The 2025 annual accounts show negative equity (-€129,158) and a net result of -€11,848. Equity fluctuates too strongly from year to year to read a trend from it. Its solvency ranks better than 17% of 271 sector peers (NACE 72, financial year 2025). The computed 12-month bankruptcy probability is 0.7% (low).
Overview
Official details
Source: KBO- Status
- Active since 29-05-2013 Normal situation
- Activity
- Research and development on biotechnology NACE 72101and 1 other
- Establishment unit
- 2.220.376.322 7700 Mouscron, since 29-05-2013
- Financial year end
- 31 December
- Peppol
- Reachable since 19-02-2025
Financial position
- Bankruptcy probabilitywithin 12 months
- 0.7%
- Gross margin
- €17,225
- ▼ 88.2%
- Turnover
- ≈ €120,000
- estimated
- Loss
- €11,848
- ▼ 90.5%
- Equity
- -€129,158
- ▼ 10.1%
- Total assets
- €597,265
- ▲ 73.7%
- Staff
- ≈ 1.9 FTE
- estimated
- Negative equity on 31-12-2025
- 2025 accounts filed 55 days after the deadline
Score breakdownraises riskCapped at 59: negative equityLast filed accounts filed 55 days late; 3 of the last 3 accounts lateNegative equity -€129,158lowers riskSize: total assets €597,265Figures for financial year 2025 (filed on 24-09-2026)Show the evidence
Checked score
About 7 in 1,000 comparable companies go bankrupt within 12 months (an estimate).
Calculation
The band follows from the bankruptcy probability. 10 more points roughly halve it.
| 75-100 | Excellent | under 0.55% |
| 60-74 | Healthy | 0.55% to 1.5% |
| 45-59 | Fair | 1.5% to 4.2% |
| 25-44 | Weak | 4.2% to 15.0% |
| 0-24 | Critical | over 15.0% |
Where the company stands within its band depends half on the bankruptcy probability and half on how it does against its sector peers (NACE 72, micro). It does better than 13% of them on solvency, 9% on liquidity, 26% on profitability and 33% on growth.
The bankruptcy probability was computed on 02-11-2026 by the bankruptcy model of 2 October 2026, which learns from Belgian bankruptcies and reads the registers, the annual accounts and the Belgian Official Gazette.
Some facts cap the score, however low the probability. With negative or zero equity, a heavy loss, a special status in the KBO, one missing filing or accounts filed more than 90 days late, the score is Fair at most (59). With two missing filings, it is Weak at most (44). During a judicial reorganisation or at the company's end (bankruptcy, dissolution, liquidation), it is Critical at most (24).
Credit check for an amount and term of your choice
Show the recommended maximum and see how the verdict changes with amount, term and advance.
The scores and ratios are Checked's own calculations, not a credit decision.
Signals
The company filed its last 7 accounts on average 194 days after the deadline. In the sector (NACE 72), the median for financial year 2024 was 13 days before the deadline, and 32% of those companies filed late.
Searched, nothing found (2)
Key points
- Risk: Negative equitydebts exceed assets in financial year 2025 -€129,158 View
- Risk: 3 loss-making years in a rowloss in financial year 2025 -€11,848 View
- Positive: Result rose in 2025different schema filed ▲ 90.5% View
- Caution: Less equity than 85% of companies in research and developmentsector median €404,064 · 272 companies -€129,158 View
Recent changes
- · Gazette deed Amendment of the articles · Legal-form change
- · Gazette deed Appointment: Antoine HALLOT (director)
- · Gazette deed Resignation: Jean VOLA (director)Appointment: Adrien VOLA (director)
Comparable companies
These companies have the same main activity as LABORATOIRES PARIS ELYSEES: research and development on biotechnology (NACE 72101). They are comparable in size and age: total assets between €376,000 and €1.2m, founded between 2009 and 2015.
| Company | Total assets | Gross margin |
|---|---|---|
| LABORATOIRES PARIS ELYSEES Mouscron | €0.6m | €0.02m |
| Ergotrics Turnhout | €0.4m | €0.03m |
| CannIbite Kontich | €0.5m | €0.06m |
| CABINET MEDICAL Geneviève MAHIEU Dinant | €0.5m | €0.04m |
| FRID MIND TECHNOLOGIES Charleroi | €1.2m | €0.04m |
| FENIXGM Fleurus | €0.8m | €0.07m |
| TRACKS&Co Jurbise | €0.5m | €0.09m |
Key facts about LABORATOIRES PARIS ELYSEES
- What is the company number of LABORATOIRES PARIS ELYSEES?
- The company number of LABORATOIRES PARIS ELYSEES is 0534.783.071. The VAT number is the same number with BE in front: BE 0534.783.071.
- Where is LABORATOIRES PARIS ELYSEES based?
- The registered office is at Kasteellaan 10, 7700 Mouscron.Company details
- What does LABORATOIRES PARIS ELYSEES do?
- According to the KBO register, the main activity is research and development on biotechnology (NACE 72101).
- What is the legal form of LABORATOIRES PARIS ELYSEES?
- The legal form of LABORATOIRES PARIS ELYSEES is Private limited company (BV).
- When was LABORATOIRES PARIS ELYSEES founded?
- LABORATOIRES PARIS ELYSEES was founded on 29-05-2013.
- Is LABORATOIRES PARIS ELYSEES still active?
- Yes, LABORATOIRES PARIS ELYSEES is an active enterprise in the KBO register.
- How many employees does LABORATOIRES PARIS ELYSEES have?
- LABORATOIRES PARIS ELYSEES had an average of 2 full-time equivalents in financial year 2024, according to the filed annual accounts.Financials
- What is the turnover of LABORATOIRES PARIS ELYSEES?
- The turnover in financial year 2025 is ≈ €120,000. This figure is estimated from the gross margin of €17,225 and 2,706 comparable companies of the same size. It probably lies between €49,000 and €290,000. It is a rough estimate.
- Is LABORATOIRES PARIS ELYSEES profitable?
- In financial year 2025, LABORATOIRES PARIS ELYSEES made a loss of €11,848.
- Where can I find the annual accounts of LABORATOIRES PARIS ELYSEES?
- LABORATOIRES PARIS ELYSEES filed 12 annual accounts with the National Bank of Belgium, the latest for financial year 2025.
- When are the next annual accounts of LABORATOIRES PARIS ELYSEES due?
- LABORATOIRES PARIS ELYSEES must file the annual accounts for financial year 2026 by 31-07-2027.Timeline
Next steps
See how customers, suppliers and banks see your own company and what to improve first.